InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
14 hedge funds and large institutions have $68.3K invested in InVivo Therapeutics Holdings Corp in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
7% less funds holding
Funds holding: 15 → 14 (-1)
42% less capital invested
Capital invested by funds: $118K → $68.3K (-$50.1K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.95K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$680 |
| 3 |
Morgan Stanley
New York
|
+$229 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$16K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$86 |
| 3 |
MIA
Milestone Investment Advisors
Middleton,
Wisconsin
|
-$2 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
BlackRock
New York
| $25.3K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $22.8K | +$1.95K | +2,300 | +8% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $13.6K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $6.13K | +$680 | +802 | +11% |
|
|
5
Morgan Stanley
New York
| $394 | +$229 | +270 | +100% |
|
|
6
Wells Fargo
San Francisco,
California
| $18 | +$1 | +1 | +4% |
|
|
7
Osaic Holdings
Scottsdale,
Arizona
| $3 | -$1 | -1 | -17% |
|
|
8
UBS Group
Zurich,
Switzerland
| $1 | -$86 | -101 | -99% |
|
|
AF
9
Allworth Financial
Folsom,
California
| $1 | – | – | – |
|
|
CTA
10
Colonial Trust Advisors
Spartanburg,
South Carolina
| $1 | – | – | – |
|
|
ITIM
11
Indiana Trust & Investment Management
Mishawaka,
Indiana
| $1 | – | – | – |
|
|
PWA
12
Provenance Wealth Advisors
Fort Lauderdale,
Florida
| $1 | – | – | – |
|
|
SWM
13
Sugarloaf Wealth Management
Duluth,
Georgia
| $1 | – | – | – |
|
|
VL
14
Vima LLC
Troy,
Michigan
| $1 | +$2 | +2 | New |
|
|
15
Renaissance Technologies
New York
| – | -$16K | -13,921 | Closed |
|
|
MIA
16
Milestone Investment Advisors
Middleton,
Wisconsin
| – | -$2 | -1 | Closed |
|
NVIV Hedge Fund Activity: Q4 2023 in Review
14 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q4 2023, worth a combined $68.3K — down 42% from $118K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NVIV and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $1.95K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $16K sold.
- 14 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q4 2023, down from 15 in Q3 2023.
- Funds reported $68.3K of InVivo Therapeutics Holdings Corp stock for Q4 2023, down 42% quarter-over-quarter.
- 1 fund opened new InVivo Therapeutics Holdings Corp positions in Q4 2023 and 2 closed out, a net change of -1 holder.
- The largest InVivo Therapeutics Holdings Corp buyer in Q4 2023 was Vanguard Group, an estimated $1.95K added.
- The largest InVivo Therapeutics Holdings Corp seller in Q4 2023 was Renaissance Technologies, an estimated $16K sold.
Based on aggregated 13F filings for Q4 2023.